Page 75 - Read Online

Ballestri et al. Metab Target Organ Damage 2023;3:13 https://dx.doi.org/10.20517/mtod.2023.21 Page 7 of 7

16. Ballestri S, Mantovani A, Girolamo MD, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients:
noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage 2023;3:1. DOI
17. Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment
Pharmacol Ther 2022;56:1119-30. DOI PubMed
18. Konyn P, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A, Kim D. Gallstone disease and its association with nonalcoholic fatty
liver disease, all-cause and cause-specific mortality. Clin Gastroenterol Hepatol 2023;21:940-948.e2. DOI PubMed
19. Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: an
observational study. Medicine 2019;98:e16018. DOI PubMed PMC
20. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver
2014;8:313-7. DOI PubMed PMC
21. Colak Y, Bozbey G, Erim T, et al. Impaired gallbladder motility and increased gallbladder wall thickness in patients with nonalcoholic
fatty liver disease. J Neurogastroenterol Motil 2016;22:470-6. DOI PubMed PMC
22. Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and Insulin resistance with non metastatic bladder cancer patients: a
cross-sectional Retrospective study. J Clin Med 2021;10:346. DOI PubMed PMC
23. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a
meta-analysis of observational cohort studies. Gut 2022;71:778-88. DOI
24. Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic
dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
Gut 2023;72:1433-6. DOI PubMed
25. Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:759-
69. DOI PubMed
26. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-
alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet
Gastroenterol Hepatol 2020;5:362-73. DOI PubMed PMC